Kiyoshi Takayama Email & Phone Number | Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was involved in the development of GPCR assay and the conducting of various drug discovery programs for chronic inflammation and chronic obstructive pulmonary disease (COPD). He also contributed to research on vascular inflammation conducted by Dr. Peter Libby (a current scientific advisor of NBHL) at Brigham and Women’s Hospital, Harvard Medical School, Boston, USA. After leaving Taisho, Takayama founded NBHL in 2006 and became the president of NBHL, with focusing on establishing a technology platform for the generation of functional mAbs targeting GPCRs to pioneer a new field in GPCR-targeted drug discovery, in collaboration with universities and other partners. As a researcher, having keen interests in chronic inflammation, which is considered the fundamental pathology in various diseases. In addition, accumulating the knowledge regarding the drug discovery solutions for multiple targeting drugs .

Kiyoshi Takayama

Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sc...
Japan

*50 free lookup(s) per month.

Kiyoshi Takayama’s Email ktakayama@nbhl.co.jp

Kiyoshi Takayama’s Phone Numbers

Get KIYOSHI’s Phone Number (For Free)

Social Media

Kiyoshi Takayama’s Location Japan

Kiyoshi Takayama’s Current Industry Nb Health Laboratory

Kiyoshi Takayama’s Prior Industry Taisho Pharmaceutical

Find accurate emails & phone numbers for over 700M professionals.

Founder And President

2006-10-01 00:00:00 - Present

Research Scientist

1994-04-01 00:00:00 - 2006-09-01 00:00:00

No Skills Available

No Languages Available

Kiyoshi Takayama is a Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was involved in the development of GPCR assay and the conducting of various drug discovery programs for chronic inflammation and chronic obstructive pulmonary disease (COPD). He also contributed to research on vascular inflammation conducted by Dr. Peter Libby (a current scientific advisor of NBHL) at Brigham and Women’s Hospital, Harvard Medical School, Boston, USA. After leaving Taisho, Takayama founded NBHL in 2006 and became the president of NBHL, with focusing on establishing a technology platform for the generation of functional mAbs targeting GPCRs to pioneer a new field in GPCR-targeted drug discovery, in collaboration with universities and other partners. As a researcher, having keen interests in chronic inflammation, which is considered the fundamental pathology in various diseases. In addition, accumulating the knowledge regarding the drug discovery solutions for multiple targeting drugs .